Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Comparisons with Ipamorelin and GHRP-6 in Sleep Research

Multiple GH secretagogues have been studied in sleep research contexts. Ipamorelin — a selective GHS-R1a agonist (ghrelin receptor) — stimulates GH release through a distinct receptor pathway (GHS-R1a vs GHRHR for sermorelin) and also promotes SWS, partly thro

This comparison does not assign a generated winner or score.

  • Multiple GH secretagogues have been studied in sleep research contexts. Ipamorelin — a selective GHS-R1a agonist (ghrelin receptor) — stimulates GH release through a distinct receptor pathway (GHS-R1a vs GHRHR for sermorelin) and also promotes SWS, partly through hypothalamic GHS-R1a signalling in sleep centres. Ipamorelin’s sleep-promoting effects may operate partially independently of GH release, through direct GHS-R1a-mediated effects on hypothalamic sleep circuits. GHRP-6, another GHS-R1a agonist, similarly promotes GH and SWS but with a pronounced appetite-stimulating side effect profile through GHS-R1a signalling in the arcuate nucleus — a mechanistic difference from sermorelin’s GHRHR-specific action.
  • Research comparing sermorelin and ipamorelin in sleep models examines whether GHRHR and GHS-R1a convergently promote SWS through shared or distinct POA circuit mechanisms. Combination sermorelin/ipamorelin protocols in aged rodent models test for additive or synergistic SWS-promoting effects, exploiting receptor-pathway complementarity — a widely used research strategy in GH secretagogue biology. CJC-1295/DAC, the long-acting GHRH analogue, provides a comparison for sustained GHRHR activation effects on sleep architecture, in contrast to sermorelin’s acute pulse-like receptor activation profile.